Mitotic microtubule (MT)-targeting drugs are widely used to treat cancer. The GTPase Ran regulates multiple processes, including mitotic spindle assembly, spindle pole formation and MT dynamics; Ran activity is therefore essential to formation of a functional mitotic apparatus. The RanBP1 protein, which binds Ran and regulates its interaction with effectors, is overexpressed in many cancer types. Several observations indicate that RanBP1 contributes to regulate the function of the mitotic apparatus: RanBP1 inactivation yields hyperstable MTs and induces apoptosis during mitosis, reminiscent of the effects of the MT-stabilizing drug taxol. Here we have investigated the influence of RanBP1 on spontaneous and taxol-induced apoptosis in transformed cells. We report that RanBP1 downregulation by RNA interference activates apoptosis in several transformed cell lines regardless of their p53 status, but not in the caspase-3-defective MCF-7 breast cancer cell line. Furthermore, RanBP1-interfered cells show an increased apoptotic response to taxol compared to their counterpart with normal or high RanBP1 levels, and this response is caspase-3 dependent. These results indicate that RanBP1 can modulate the outcome of MT-targeting therapeutic protocols.
Introduction
Assembly of mitotic microtubules (MTs) into a bipolar spindle is essential for balanced chromosome transmission to newly generated daughter cells at mitosis. Drugs that target MTs are widely used in chemotherapeutic treatment of cancer (reviewed by Bhalla, 2003; Mollinedo and Gajate, 2003; Jordan and Wilson, 2004; Weaver and Cleveland, 2005; Jackson et al., 2007) . Among these, taxanes, of which taxol (paclitaxel) is a member, induce MT hyperstabilization and impair their dynamic activity: cells therefore cannot progress through mitosis and either remain mitotic-arrested or are eliminated through apoptosis. Some cells, however, escape mitotic arrest and complete mitosis with abnormal MTs, forming aneuploid or polyploid cells; if such cells are not eliminated in the following G 1 phase on activation of the post-mitotic checkpoint, they can initiate a high-risk genetically unstable cellular clone (reviewed by Kops et al., 2005; Yamada and Gorbsky, 2006; Weaver and Cleveland, 2007) .
In the past years, much work has sought to clarify the molecular mechanisms underlying apoptosis induction by MT-targeting agents, including taxol. Not all mechanisms are as yet completely understood, partly due to the high variability of the cellular responses to taxol, not only between cell lines (Ofir et al., 2002; Shi et al., 2008) , but also among individual cells within the same line (Gascoigne and Taylor, 2008) . The existence of variations between cell types, and even between cells sharing a homogeneous genetic background, has somewhat complicated the identification of involved signaling molecules. Some features however are beginning to emerge (see reviews by Bhalla, 2003; Mollinedo and Gajate, 2003; Impens et al., 2008; McGrogan et al., 2008 and references therein) apoptosis induction from mitosis is regulated by caspase-3; it does not require p53, which is instead required in the post-mitotic checkpoint that regulates apoptosis induction in G 1 after override of mitotic arrest. Caspase-3 activation by MT-stabilizing drugs induces a Bcl2/Bax pathway; mitogen-activated protein kinases (MAPKs), including Erk1/2 and p38, are also activated in many cell types on mitotic damage (Bacus et al., 2001) .
Genes that regulate the mitotic apparatus can contribute to reduce or amplify the extent of druginduced MT damage, hence influencing the sensitivity of cells to these drugs. These genes are often abnormally expressed in gene profiling studies of cancer cells versus their healthy counterpart (Bhat and Setaluri, 2007; Pe´rez de Castro et al., 2007) . Oncological patients, however, are currently treated with MT-targeting drugs following empirically established regimen, which rarely take into account the status or expression profile of mitotic genes in cancer cells. Progress in the identification of genes capable of modulating the outcome of MT-targeting drugs is therefore an important step toward optimizing therapeutic strategies in relation to the gene expression profile of particular cancers.
The RanBP1 protein is a partner of Ran, a versatile GTPase that regulates diverse processes, including mitotic spindle organization and dynamics. As for all GTPases, Ran function depends on its binding to either GTP or GDP. RanBP1 regulates nucleotide turnover on Ran by stimulating the hydrolysis-activating protein RanGAP1, thereby facilitating RanGDP formation, and inhibiting the guanine exchange factor RCC1, thus preventing GTP exchange on Ran: both activities converge in reducing the concentration of available RanGTP (Bischoff et al., 1995) . RanBP1 also exerts an important function in modulating the interaction of RanGTP with its effectors (Plafker and Macara, 2000; Goerlich et al., 2003) .
Many factors acting in mitotic spindle assembly, spindle pole formation, MT dynamics and spindle checkpoint, are sensitive to the activity of Ran, its partners and effectors. GTP-bound Ran activates a large set of factors in these processes, whereas the major Ran effector, importin-b, exerts an antagonistic function by engaging these factors in complexes in which they are 'shielded' from RanGTP-dependent activation. Ran and importin-b are therefore viewed as global mitotic regulators (reviewed by Ciciarello et al., 2007; Clarke and Zhang, 2008; Kalab and Heald, 2008) . The bulk of RanGTP localizes to chromosomes, but Ran network components also localize at specific structures of the mitotic apparatus in somatic mitotic cells and modulate the activity of MT-regulatory factors therein (reviewed by Di Fiore et al., 2004) . In particular, RanBP1 associates with the spindle MTs with an accumulation at spindle poles (Di Fiore et al., 2003) , and therein colocalizes with a fraction of Ran and importin-b ; all three components are also present in purified mitotic MT preparations in cosedimentation assays (Tedeschi et al., 2007) . Noteworthily, genes encoding Ran and its partners are increasingly found to be aberrantly expressed in transformed and cancer cells (also see Abe et al., 2008; Kurisetty et al., 2008; Rensen et al., 2008; Xia et al., 2008a and references therein) .
RanBP1 is the only cell-cycle-regulated Ran network component in mammalian cells, with highest abundance in G 2 and M phases. It is transcriptionally regulated by the E2F/Rb pathway (Di Matteo et al., 1995; Di Fiore et al., 1999; Ishida et al., 2001) and is aberrantly expressed in many cancers (Rensen et al., 2008) . To understand how high RanBP1 levels might affect cell transformation, we previously induced RanBP1 overexpression in cultured cells: this caused the formation of multipolar mitotic spindles (Guarguaglini et al., 2000; Di Fiore et al., 2003) . Roles of RanBP1 in control of MT function also emerge from RNA interference (RNAi) experiments: RanBP1-downregulated cells assemble mitotic spindles that are apparently normal but have altered properties, including resistance to MT depolymerization induced by chemical or physical agents, failure to associate with cyclin B1 and abnormal recruitment of the MT-stabilizing factor HURP (hepatoma up-regulated protein, itself viewed as a potential oncogene). HURP normally localizes to MT plus-ends and contributes to stabilize MT/kinetochore attachments (Koffa et al., 2006; Sillje et al., 2006; Wong and Fang, 2006) , but it acquires a widespread distribution along the entire MT length on RanBP1 inactivation (Tedeschi et al., 2007) . The resulting hyperstable MTs prolong or arrest prometaphase in video-recording experiments; many RanBP1-interfered cells actually undergo apoptosis after prolonged prometaphase delay, or progress further into mitosis and undergo inaccurate chromosome segregation (Li et al., 2007; Tedeschi et al., 2007) . These features are reminiscent of the effects of taxol. We therefore wondered whether RanBP1 abundance may influence the cell sensitivity to taxol; this is a relevant question, given the frequent occurrence of altered RanBP1 expression in cancers (Rensen et al., 2008) , many of which are treated with drugs of the taxane family. We now report that RanBP1 downregulation triggers a specific apoptotic response that requires caspase-3, whereas p53 is not involved. Moreover, we demonstrate that reducing RanBP1 levels in transformed cells renders them more sensitive to apoptosis induction by taxol. These results indicate that RanBP1 does indeed influence the therapeutical outcome of MT-stabilizing drugs.
Results

RanBP1 interference in U2OS cells results in apoptosis induction independent on p53
Having previously found that RanBP1 downregulation yields hyperstable MTs and induction of apoptosis (Tedeschi et al., 2007) , we sought to gain insight into the apoptotic machinery involved. To that aim we transfected U2OS osteosarcoma cells for 48 h with two smallinterfering RNA oligonucleotides (siRNAs, indicated as 202 and 459 in the map in Figure 1a ) that specifically silence the RanBP1 gene, or with an siRNA targeting the nonhuman luciferase gene (GL2). Early apoptotic cells were identified from 4,6-diamidino-2-phenyl indole (DAPI) staining, revealing chromatin condensation, and immunofluorescence (IF) to lamin B1, which is cleaved during early apoptosis. We found a significant increase in apoptotic cells in cultures treated with RanBP1-specific siRNAs compared to GL2-interfered control cultures (Figure 1b) , consistent with previous studies (Li et al., 2007; Tedeschi et al., 2007) . We next stained the cells with a specific antibody for active caspase-3, an important regulator of apoptosis. Parallel U2OS samples were exposed to staurosporine and dimethyl sulfoxide (DMSO), as positive and negative controls for caspase-3 induction, respectively. As shown in Figure 1c , active caspase-3 is upregulated in both 202 and 459 RanBP1-interfered cultures, similar to staurosporine-exposed cultures, whereas levels remain barely detectable in both control (GL2) and DMSOexposed cells. More than 1000 cells per sample were counted in two experiments (Po0.01 between caspase-3-positive cells in RanBP1-interfered compared to GL2-interfered cultures). The lower panels ( Â 100 objective) show a comparable caspase-3 signal intensity in interfered cells using either RanBP1-specific siRNA or in cells exposed to staurosporine (stau), whereas signals in dimethyl sulfoxide (DMSO)-exposed and GL2-interfered cells are barely detectable (bar, 10 mm). (d) Western blot analysis of U2OS cell cultures interfered for the indicated times with RanBP1-specific 202 ( þ ) or control (À) siRNA. Note that the two western blot panels show the same time-course analysis, but the left panel is loaded so as to directly compare RanBP1-interfered ( þ ) and control (À) cell extract at the same time point, loaded alongside, whereas in the right panels all controls and interfered samples were grouped to help visualizing the response of apoptotic markers over time.
Caspase-3 activity is regulated, among others, by members of the MAPKs (Lu and Xu, 2006 and references therein). Active caspase-3, in turn, cleaves poly(ADP-ribose) polymerase (PARP) (Nicholson et al., 1995; Tewari et al., 1995) . To establish whether a caspase-3-dependent pathway is involved in the response to RanBP1 downregulation, we compared protein levels of U2OS cultures interfered for either RanBP1 or GL2 for increasing lengths of time. Using antibodies to active, phosphorylated (P) MAPK forms, we found that p38 and Erk1/2 members were activated over time, with a time-course that paralleled the induction of apoptosis ( Figure 1d ). In parallel, PARP was increasingly cleaved. In contrast, p53 levels did not vary during RanBP1 interference. These data indicate that RanBP1 downregulation triggers an apoptotic response that involves caspase-3, Erk1/2, p38 and PARP but not p53.
RanBP1 downregulation induces apoptosis mediated by caspase-3
To further characterize the apoptotic response to RanBP1 depletion, we analyzed transformed cell lines expressing defined sets of apoptotic regulators: in addition to U2OS cultures used thus far (p53
, we examined breast cancer-derived cell lines MDA-MB231 (high malignancy grade, p53
, expressing functional caspase-3) and MCF-7 (low grade, p53
þ / þ , lacking caspase-3). RNAi experiments were carried out for 24 h and early apoptotic cells were scored by microscopy. To reliably compare cell lines and correct for possible differences in the efficiency of siRNA transfection, we used Cy3-labeled 202 siRNA, so that truly interfered cells could be directly visualized from their red fluorescence emission. Using chromatin condensation and loss of lamin B1 as markers, as above, we found increased apoptosis among Cy3-positive RanBP1-interfered cells compared to control samples in both the U2OS and MDA-MB231 cell lines, but not in the MCF-7 caspase-3-defective culture (Figure 2a ). To distinguish whether MCF-7 cells were simply delayed or truly defective in apoptosis induction by RanBP1 downregulation, we prolonged the time of RNAi to 72 h. After propidium iodide (PI) incorporation in genomic DNA, we examined the appearance of hypodiploid (o2C, hence completely apoptotic) cells by fluorescence-activated cell sorting (FACS). We found apoptosis induction in RanBP1-interfered MDA-MB231 breast cancer cells (Figure 2b ): this unambiguously indicates that functional p53 is not required for the apoptotic response to RanBP1 downregulation. Instead, RanBP1 interference failed to induce apoptosis in MCF-7 cells even after prolonged RNAi. To establish whether caspase-3 deficiency was responsible for the lack of apoptosis in RanBP1-interfered MCF-7 cells, we assessed the response of an MCF-7-derived cell line reconstituted with caspase-3 (Yang et al., 2001) . The derivative line effectively induced apoptosis in response to RanBP1 interference (Figure 2b ), formally demonstrating that the apoptotic pathway triggered by RanBP1 downregulation is dependent on caspase-3 function. Western blot analysis confirmed these findings (Figure 2c ): all cell lines but MCF-7 showed (1) accumulation of mature caspase-3 forms cleaved from procaspase and (2) significantly decreased levels of lamin B1, a typical substrate of active caspase-3, in cultures with downregulated RanBP1 levels. These results indicate that RanBP1 downregulation triggers caspase-3-dependent apoptosis induction.
Downregulation of RanBP1 levels render U2OS cells more sensitive to taxol
The involvement of caspase-3 in the apoptotic response to RanBP1 downregulation is interesting in light of the notion that taxol, which suppresses MT dynamics and causes prometaphase arrest, also induces caspase-3 activation and eventually apoptosis (Ibrado et al., 1998; Oyaizu et al., 1999; Wieder et al., 2001; Lu et al., 2005; Impens et al., 2008) . We therefore decided to investigate the combined effect of RanBP1 interference and taxol exposure. Given that U2OS cells are reported to have a somewhat loose spindle checkpoint (Brito and Rieder, 2008) , we first examined the effectiveness of mitotic block induced by taxol. U2OS cells were exposed to 100 nM or 10 mM taxol and the cell-cycle profile of PI-stained samples was analyzed by FACS. After 12 h, both doses induced an effective G 2 /M block (68 and 84% of all cells had a 4C DNA content), which was stably maintained after 18 h of exposure (data not shown). We next compared apoptosis induction by taxol in control and RanBP1-depleted U2OS cultures. We used fluorescein isothiocyanate (FITC)-conjugated Annexin V to detect phosphatidylserine residues translocated from the inner to the outer plasma membrane already at early stages of apoptosis induction. FACS analysis demonstrated an increase in the fraction of Annexin V-positive cells after 24 h of taxol exposure in RanBP1-interfered compared to GL2-interfered cultures (Figure 3a) . Results quantified in Figure 3b indicate a statistically significant increase in apoptosis induction by 100 nM taxol in RanBP1-depleted, compared to GL2-interfered control cultures. Most importantly, in RanBP1-interfered cultures exposed to 100 nM taxol, apoptosis reached a comparable level to that induced by 10 mM taxol in control cultures. In western blot assays, lamin B1 was degraded with higher efficiency, whereas caspase-3 was activated, in RanBP1-interfered compared to GL2-interfered cultures at both taxol doses (Figure 3c ). Thus, RanBP1 downregulation renders U2OS cells more sensitive to taxol-induced apoptosis.
RanBP1 downregulation increases apoptosis in taxol-exposed HeLa cells
The RanBP1 gene is regulated by the E2F/Rb pathway (Di Fiore et al., 1999) and is highly expressed in cervical epithelial HeLa cells, in which that pathway is dysregulated due to human papillomavirus (HPV) transformation. Furthermore, taxol is especially used in clinics to treat breast epithelial, cervical, lung and other carcinomas, rather than osteosarcoma (Mollinedo and Gajate, 2003; Jordan and Wilson, 2004) . It was of relevance, therefore, to investigate whether RanBP1 downregulation would also modulate the outcome of taxol treatment in HeLa cells. Western blot assays to test the effectiveness of RanBP1 interference in HeLa cells indicate that RanBP1 abundance began to decrease after 48 h of interference and, after 60 h, dropped to 20% of that seen in control cells (Figure 4a ). In parallel, lamin B1 was degraded, whereas levels of P-Erk1/2 and of cleaved PARP increased, indicating a gradual induction of apoptosis. HeLa cells are functionally p53 À/À due to the presence of HPV-encoded E6 oncoprotein, confirming therefore that p53 is dispensable for the apoptotic response to RanBP1 downregulation.
We next characterized the response of HeLa cells in dose-response experiments with five taxol concentrations (1 nM to 10 mm). We found that (1) concentrations above 10 nM induced an effective G 2 /M block (over 70% of all cells had a 4C content by FACS analysis after 24 h of exposure); (2) practically all 4C cells were mitotic figures, as revealed by fluorescence microscopy of DAPI-and a-tubulin-stained cultures; (3) multinucleated cells, resulting from override of mitotic arrest, were only induced with the lowest concentration (1 nM) but not above (data not shown). Thus, 10 nM or higher concentrations of taxol effectively block mitotic progression in HeLa cells. At this point we examined the influence of RanBP1 levels on apoptosis induction by taxol. HeLa cultures were interfered for RanBP1 or GL2 (48 h) and exposed to increasing taxol concentrations during the last 24 h of culture, as previously done with U2OS. To depict apoptosis accurately, we simultaneously incubated cell samples with FITC-conjugated Annexin V and PI, with no prior permeabilization step: this allowed to discriminate viable, early apoptotic, late apoptotic and necrotic cells in biparametric FACS analysis (Figure 4c ). The analysis showed that RanBP1-downregulated HeLa cultures achieved higher apoptosis induction compared to control cultures at all taxol doses (Figure 4c , left panels). Taxol is reported to be particularly effective when the length of exposure spans more than one cell cycle (Wang et al., 1999) . We therefore extended the combined RNAi/taxol protocol to another 24 h (corresponding roughly to one more cell cycle) (Figure 4c , right panels). Under these conditions, RanBP1-downregulated cultures achieved massive apoptosis (up to 75% of all cells) already with the lowest taxol dose (10 nM), whereas control-interfered cells did not exceed 40% of apoptosis induction at the same dose, and only reached 50% with the highest taxol concentration. Consistent with this, western blot assays revealed higher caspase-3 induction and more effective lamin B1 degradation in RanBP1-interfered compared to GL2-interfered HeLa cells after taxol exposure (Figure 4b ). These data indicate that taxol-induced apoptosis in HeLa cells can indeed dramatically increase when RanBP1 abundance is reduced.
Caspase-3 mediates apoptosis induction by combined RanBP1 interference and taxol Given that caspase-3 is involved in apoptosis induction by low RanBP1 levels, we wished to ascertain whether caspase-3 is actually indispensable for RanBP1-depleted cells to activate taxol-dependent apoptosis. To address that question, we compared taxol effects in RanBP1-downregulated and in proficient (GL2-interfered) MCF-7 cells lacking caspase-3 and in its caspase-3 reconstituted derivative. HeLa cultures were analyzed in parallel for comparison. RNAi was carried out for 72 h using the Cy3-tagged siRNA, and taxol (100 nM) was applied during the last 24 h. Red-emitting (that is, interfered) cells were scored and apoptotic cells were identified by microscopy from their condensed chromatin (DAPI staining) and loss of lamin B1. We found that RanBP1 downregulation leads to a significant increase (Po0.01) of taxol-induced apoptosis in HeLa and MCF-7/casp-3, but not in MCF-7 cell cultures (Figure 5a) . These results at the single-cell level were consistent with FACS analysis at the cell populationwide level (Figure 5b ): MCF-7 undergo effective G 2 /M arrest in the presence of taxol, but fail to induce significant apoptosis, with or without RanBP1. Forced expression of caspase-3 in the MCF-7/casp-3 derivative restores effective apoptosis induction by taxol; RanBP1-depleted cultures show a further increase in the sub-G 1 (o2C) fraction, and a smaller G 2 /M fraction, compared to cultures exposed to taxol alone, consistent with activation of apoptosis during mitosis. Together these experiments indicate that caspase-3 is not only involved, but is actually required, for activation of apoptosis by taxol in cells with downregulated RanBP1 levels.
Discussion
Proteins with spindle-organizing and/or MT-regulatory activity can antagonize, or synergize with MT-targeting drugs, depending on their mechanism of action. Their level of expression can therefore be critical in modulating the ability of these drugs to induce mitotic arrest and/or cell death. That has lead to test the proposal, in several laboratories, that experimental manipulation of the expression of genes coding for these proteins may be combined with MT-targeting drugs to improve their therapeutical efficacy. Well-documented instances include the genes encoding the mitotic protein kinases PLK1 (Spa¨nkuch et al., , 2007 and Aurora-A (Anand et al., 2003; Jiang et al., 2003; Hata et al., 2005; Tanaka et al., 2007) , the MT-binding protein stathmin/ OP18, which has MT-destabilizing activity (Iancu et al., 2000 (Iancu et al., , 2001 Alli et al., 2002) , and survivin, a member of the kinetochore-associated passenger proteins with MTstabilizing activity (Giodini et al., 2002; Carvalho et al., 2003; reviewed by Altieri, 2008) . Relevant to the work reported here, survivin has been recently found to interact directly with Ran (Xia et al., 2008a, b) . Cyclin B1 also influences taxol-dependent apoptosis . Cyclin B1/cdk1 complexes associate with MTs and regulate their dynamics (Verde et al., 1992) and have recently been shown to regulate caspase-9 activity in response to MT drugs (Allan and Clarke, 2007) .
We and others previously reported that RanBP1 regulates MT stability. We have now induced RNAimediated downregulation of RanBP1 in cell lines expressing distinct sets of apoptotic regulators. We show that RanBP1 depletion triggers a specific apoptotic pathway that is independent on p53 but involves PARP, Erk1/2 and p38. In addition, caspase-3 is indispensable in this response, because the breast cancer cell line MCF-7, which is p53 proficient but caspase-3 defective, fails to induce apoptosis in response to RanBP1 downregulation; however, reintroduction of caspase-3 activity in this cell line (Yang et al., 2001 ) is sufficient to restore the apoptotic response. Intriguingly, caspase-3 is expressed in a cell-cycle-dependent manner, with highest levels at mitotic onset, and, among other substrates, can cleave BubR1: through this activity, caspase-3 is thought to contribute to release the spindle checkpoint-dependent mitotic arrest and target cells toward apoptosis (Kim et al., 2005) . The features induced by RanBP1 downregulation described above show striking analogies with those depicted during taxol induction of apoptosis in mitotic cells.
Apoptosis induction during faulty mitosis has recently been shown to require cyclin B1 levels above a minimal threshold (as complete cyclin B1 degradation would determine mitotic exit and 'slippage' to the next interphase), concomitant with the accumulation of caspase-dependent death signals (Gascoigne and Taylor, 2008) . In previous video-microscopy experiments, RanBP1-depleted cells were found to activate apoptosis after prolonged delay in prometaphase (Li et al., 2007; Tedeschi et al., 2007) , a stage at which cyclin B1 is abundant in the cell. In addition, RNAi-mediated RanBP1 inactivation prevents the association of cyclin B1 with mitotic spindle MTs (Tedeschi et al., 2007) . Given that cyclin B1 destruction in anaphase occurs in association with the spindle MTs (Huang and Raff, 1999) , it is possible that RanBP1-interfered cells, which delocalize cyclin B1 from the spindle, delay cyclin B1 degradation. Thus, RanBP1 downregulation creates conditions that favor cyclin B1 persistence, concomitant with the accumulation of caspase-3, which are major determinants of the apoptotic response to taxol (Holland and Cleveland, 2008) .
Both RanBP1 and Ran are associated with mitotic MTs and spindle poles. RanBP1 inactivation by siRNAs (Tedeschi et al., 2007) or by a specific antibody (Guarguaglini et al., 2000) renders MTs resistant to depolymerizing agents, indicating increased stability. These features suggest that low RanBP1 abundance and taxol converge in targeting MTs and triggering a similar signaling response. It is worth recalling that, conversely, RanBP1 excess synergizes at various levels with MT-depolymerizing drugs. NOC inhibits MT polymerization and spindle assembly by direct tubulin binding, but this effect is completely reversible after NOC washout. RanBP1 overexpression enhanced the effects of NOC in mammalian cells and hindered the resumption of MT assembly after NOC washout (Battistoni et al., 1997) . The hindrance caused by high RanBP1 levels (which yield low RanGTP concentrations) likely reflects the requirement of RanGTP for proper resumption of MT polymerization and spindle assembly, thus rendering NOC effects more severe and more persistent. These data in mammalian cells are consistent with early evidence that in Schizosaccharomyces pombe, overproduction of CST20, the yeast homologue of mammalian RanBP1, confers sensitivity to the MT-depolymerizing drug benomyl (Ouspenski et al., 1995) . In summary, therefore, consistent lines of evidence indicate the importance of RanBP1 levels in modulation of MT stability: high RanBP1 levels and MT-depolymerizing agents have synergistic effects, whereas RanBP1 depletion is synergic with the MT-stabilizing activity of taxol.
The finding that reducing RanBP1 levels sensitizes cancer cells to taxol-dependent apoptosis in a manner that requires caspase-3 can have relevant implications for the outcome of treatment in cancer types in which RanBP1 is aberrantly expressed. In particular, carcinomas are routinely treated with taxol, the effect of which might be counteracted by high RanBP1 abundance. In that respect, the response of HeLa cells is worth noting as a paradigmatic example of a RanBP1-overexpressing carcinoma cell line: indeed, RanBP1 is overexpressed in cells expressing adenovirus E1A or HPV E7, which disrupt Rb control (Di Matteo et al., 1995) ; furthermore, E7 interacts with Ran directly, and can thereby cause further deregulation of the Ran cycle (De Luca et al., 2003) . Indeed, we now show that downregulation of RanBP1 abundance renders HeLa cells highly sensitive to taxol concentrations that have limited effect in their noninterfered counterpart. In retrospect, these observations provide a molecular explanation for the empirical finding that the sensitivity of human breast cancer cells to docetaxel is actually influenced by endogenous RanBP1 levels, and that resistant cancer samples tend to express higher RanBP1 levels compared to sensitive samples (Geoprofile accession GDS360). Finally, it is of interest that siRNA-mediated RanBP1 downregulation also increased the apoptotic response to taxol in U2OS cells. The spindle checkpoint is reported to be somewhat loose in those cells, which do only transiently arrest mitosis in the presence of MT damage, but subsequently 'slip' through the checkpoint and progress to divide (Brito and Rieder, 2008) . The finding that lowering RanBP1 abundance facilitates apoptotic induction by taxol in U2OS cells therefore suggests that high stringency of the spindle checkpoint is dispensable for this response.
In conclusion, the data reported here indicate a functional interplay between levels of endogenous RanBP1 and the effectiveness of MT-targeting drugs. These findings highlight a novel aspect of RanBP1 function at the crossroad between regulation of MT stability and apoptosis induction. They also underscore a caveat against the use of MT-stabilizing drugs to treat cancer cells with no knowledge of the status of Ran network members, as high RanBP1 levels hinder the apoptotic response to these drugs. More generally, the present findings indicate that chemotherapy using MT drugs should be tailored to the status of mitotic genes in particular cancer types.
Materials and methods
Cell cultures and treatment
Human U2OS osteosarcoma, HeLa epithelial cells and the breast cancer cell lines MCF-7 and MDA-MB231 were all from American Type Culture Collection. MCF-7/casp-3 were kindly given by Dr Chris Froelich. All cell lines were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (20% for MCF-7/casp-3) at 37 1C with 5% CO 2 . Taxol and staurosporine (both from Sigma-Aldrich, St Louis, MO, USA) were dissolved in DMSO and used at the indicated concentrations (taxol) or 1 mM (staurosporine) with a final DMSO concentration of 0.5%.
RNA interference
Cells were transfected with siRNA GL2, targeting the firefly luciferase gene, with RanBP1-specific siRNAs 202 (GGAGCG AGGCACUGGUGAC) and 459 (AGUUUGAAGAAUGCA GGAA) (all from Qiagen, Hilden, Germany), or with Cy3-labeled 202 siRNA (Dharmacon Research, Chicago, IL, USA). The 202 siRNA was used in most experiments unless otherwise indicated. siRNAs were used 60 nM (U2OS, HeLa and MDA-MB231 cells) or 90 nM (MCF-7 and MCF-7/casp-3) and were transfected into cells using oligofectamine (Invitrogen, Carlsbad, CA, USA) as given in Tedeschi et al. (2007) .
IF and microscopy
Cells grown on sterile coverslips were fixed in 3.7% paraformaldehyde and permeabilized in phosphate-buffered saline containing 0.1% Triton X-100, then incubated with the following primary antibodies: rabbit anti-lamin B1 (ab16048, 1:500; Abcam, Cambridge, UK), rabbit anti-active caspase-3 (ab13847, 1:200; Abcam), mouse anti-a-tubulin (clone B5.1.2, 1:2000; Sigma-Aldrich), goat anti-RanBP1 (C-19) (sc-1160, 1:25; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and, after extensive washes, with the secondary antibodies: donkey anti-rabbit FITC (sc-2090, 1:100; Santa Cruz Biotechnology), donkey anti-rabbit Cy3 (711-165-152, 1:1000; Jackson Immunoresearch Laboratories, West Grove, PA, USA), horse anti-mouse Texas Red (TI-2000, 1:800; Vector Laboratories, Burlingame, CA, USA) or goat anti-mouse FITC (115-095-068, 1:200; Jackson Immunoresearch Laboratories). The DNA was stained with DAPI (0.1 mg/ml; Sigma-Aldrich) and coverslips were mounted in Vectashield (Vector Laboratories). Cells were examined under an epifluorescence Olympus AX70 microscope with a CCD camera (Photometrics, Tucson, AZ, USA).
FACS analysis
Apoptosis was analyzed after incubation with PI (SigmaAldrich) alone, Annexin V-FITC (IK-11120; Immunological Sciences, Rome, Italy) staining alone or Annexin V-FITC in combination with PI. Cell samples were analyzed in a Coulter Epics XL cytofluorometer (Beckman Coulter, Fullerton, CA, USA) equipped with EXPO 32 ADC software. At least 10 000 cells per sample were acquired.
Western blotting
Protein extracts were separated through SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose filters, blocked and incubated with the following primary antibodies: goat anti-RanBP1 (C-19) (sc-1160, 1:200) and goat anti-actin (I-19) (sc-1616, 1:400) both from Santa Cruz Biotechnology; rabbit anti-phospho-p38 MAPK (9211, 1:1000), rabbit anti-PARP (9542, 1:1000), rabbit anti-phospho-Erk1/2 (p44/42) MAPK (9101, 1:1000), rabbit anti-cleaved caspase-3 (9661, 1:500), all from Cell Signaling Technology (Danvers, MA, USA); rabbit polyclonal anti-lamin B1 (ab16048, 1:1000) from Abcam; and mouse monoclonal anti-p53 antibody (clone DO-7, 1:800; DakoCytomation, Glostrup, Denmark). Horseradish peroxidase-conjugated secondary antibodies (donkey anti-goat 1:5000, goat anti-mouse 1:5000 and goat anti-rabbit 1:7000 from Santa Cruz Biotechnology; goat anti-rabbit 1:1000 from Cell Signaling Technology) were revealed with enhanced chemiluminescence (ECL) or ECL plus (GE Healthcare, Chalfort Saint Giles, UK).
Statistical analysis
All experiments were repeated as indicated in the text. Independently repeated experiments were compared by calculating the standard deviations (s.d.) between mean values. In most cytological experiments, cell counts from different experiments (with at least 400 cells counted in each experiment) were pooled and the differences between samples were statistically evaluated using the w 2 -test.
